SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Thicair is a product combining microneedling and subdural vitamins for hair loss, containing ingredients like Panax Ginseng Root Extract and Copper Tripeptide-1. Users are skeptical, with one calling it "quackery."
Female with PCOS experiences receding and thinning hair, wants dutasteride instead of spironolactone. Discusses desire to reduce DHT without losing libido.
A user shared a DIY recipe for a NutraKos-style amino acid mix as a cost-effective alternative to the expensive product, suggesting it as a complementary supplement for hair loss. Another user argued that proven treatments like finasteride and minoxidil are more reliable, questioning the efficacy of the amino acid mix.
In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.
The user has been using finasteride and minoxidil since October 2023 and is concerned if a supplement containing L-arginine, L-citrulline, Tongkat Ali, Tribulus terrestris, Avena Sativa, Gingko Biloba, Ginseng, Pyridoxine, Zinc Gluconate, and Saw Palmetto can cause hair loss. They report thicker and denser hair despite ongoing shedding.
A product called "PP405 Hair Follicle Serum" is being sold on Shopee, claiming to cure baldness without clinical trials or FDA approval, but users are skeptical and refer to it as "snake oil." Some users discuss testing the product's contents, while others share their experiences with hair loss treatments like finasteride.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.